Lumrotatug

{
  "id": "MLC-T-ONC-014902",
  "term": "Lumrotatug",
  "field": "Oncology and biomedicine",
  "definition": "A monoclonal antibody directed against the human cell surface glycoprotein ADP-ribosyl cyclase 1 (CD38), with potential antineoplastic activity. Upon administration, lumrotatug specifically targets and binds to CD38 expressed on tumor cells. This may trigger antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), antibody-dependent cellular phagocytosis (ADCP) and apoptosis, resulting in cell lysis and depletion of CD38-expressing tumor cells. In addition, lumrotatug inhibits the extracellular enzyme activity of CD38. CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies. It plays an important role in the regulation of migration and receptor-mediated adhesion, as well as various cell functions through its multiple ecto- and endo-enzymatic activities.",
  "synonyms": [
    "anti-CD38 monoclonal antibody CM313"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/lumrotatug/"
}